MedinCell SA

As of March 31, 2026, Medincell carries a market capitalization of 1.21B, placing it among publicly traded companies globally. Its enterprise value stands at 1.17B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Medincell's next confirmed earnings release is scheduled for December 9, 2026.

As of March 31, 2026, Medincell has 35.91M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Medincell maintains a current ratio of 4.67, meaning it holds 4.7x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

As of the close on October 20, 2026, Medincell's stock has gained approximately 333.79% over the past 52 weeks.

As of March 31, 2026, Medincell holds 98.05M in cash and equivalents against 66.36M in total debt, resulting in a net debt position of -8.98M. Total book value stands at 3.54M, with working capital of 87.88M providing operational flexibility.